In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Verve Therapeutics (VERV – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $17.54.
Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. According to TipRanks, Issi has an average return of -16.2% and a 32.02% success rate on recommended stocks.
Currently, the analyst consensus on Verve Therapeutics is a Moderate Buy with an average price target of $38.33.
See the top stocks recommended by analysts >>
VERV market cap is currently $1.06B and has a P/E ratio of -4.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verve Therapeutics (VERV) Company Description:
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
Read More on VERV:
